Search

Displaying results 3181 - 3190 of 7452 in total
  1. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  2. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and no...

  3. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Pegvaliase-pqpz, or PEGylated pegvaliase, is used as a novel enzyme substitution therapy and is marketed as Palynziq for subcutaneous injection. … [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering

  4. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    It is approved for use in Japan.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]

  6. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

  7. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  8. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  10. Drug

    Meclocycline

    go.drugbank.com/drugs/DB13092
    Investigational

    Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .

    Categories: Anti-Acne Preparations for Topical Use, Antiinfectives for Treatment of Acne